Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well vorinostat works in treating
patients with primary cutaneous T-cell lymphoma. Vorinostat may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth